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Abstract
Epidemiologic studies have identified a number of lifestyle factors, e.g. diet, obesity, and use of
certain medications, which affect risk of colon cancer. However, the magnitude and significance of
risk factor-disease associations differ among studies. We propose that population trends of
changing prevalence of risk factors explains some of the variability between studies when factors
that change prevalence also modify the effect of other risk factors. We used data collected from
population-based control who were selected as study participants for two time periods, 1991–
1994 and 1997–2000, along with data from the literature, to examine changes in the population
prevalence of aspirin and non-steroidal anti-inflammatory medication (NSAID) use, obesity, and
hormone replacement therapy (HRT) over time. Data from a population-based colon cancer case-
control study were used to estimate effect-measurement modification among these factors.
Sizeable changes in aspirin use, HRT use, and the proportion of the population that is obese were
observed between the 1980s and 2000. Use of NSAIDs interacted with BMI and HRT; HRT use
interacted with body mass index (BMI). We estimate that as the prevalence of NSAIDs use changed
from 10% to almost 50%, the colon cancer relative risk associated with BMI >30 would change from
1.3 to 1.9 because of the modifying effect of NSAIDs. Similarly, the relative risk estimated for BMI
would increase as the prevalence of use of HRT among post-menopausal women increased. In
conclusion, as population characteristics change over time, these changes may have an influence on
relative risk estimates for colon cancer for other exposures because of effect-measure
modification. The impact of population changes on comparability between epidemiologic studies
can be kept to a minimum if investigators assess exposure-disease associations within strata of
other exposures, and present results in a manner that allows comparisons across studies. Effect-
measure modification is an important component of data analysis that should be evaluated to obtain
a complete understanding of disease etiology.
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Background
Epidemiologic investigations have detected associations
between colon cancer and several diet and lifestyle risk
factors, but the relative importance of risk factors has
changed over time [1,2]. Studies of diet and colon cancer
conducted in the early 1980s showed that fat was statisti-
cally significantly associated with colon cancer, but more
recent studies have not supported that association [3-6].
More recently use of aspirin and hormone replacement
therapy (HRT) have emerged as being statistically signifi-
cant risk factors for colon cancer as well as significantly
interacting with other risk factors [7-9]. For example, it
has been shown that the association between obesity as
indicated by a high body mass index (BMI) and increased
relative risk of colon cancer is influenced by estrogen or
hormone replacement therapy use [10,11]; reports sug-
gest that aspirin may influence the colon cancer relative
risk associated with fat intake [12,13]; other data support
the role of effect modification on diet and lifestyle factors
in colon cancer etiology [12,14].
Inconsistencies in results for risk factor-disease associa-
tions for colon cancer have been attributed to a variety of
non-biological factors. Since earlier results for colon can-
cer came primarily from case-control studies, while cohort
studies contributed more to the recent literature, study
design, i.e. the potential biased reporting in case-control
studies, has been cited as a potential explanation for dif-
ferences between results of older and more recent stud-
ies[15]. However, results of cohort studies may be affected
by measurement error from imprecise exposure assess-
ment when data are collected using a self-administered
format. Thus case-control and cohort studies each have
strengths and weaknesses, yet many risk factor associa-
tions are observed to be similar from both case-control
and cohort studies. While random and systematic errors
may explain differences in study results, even for similar,
well-conducted studies, a very plausible explanation for a
trend in study results is a change in prevalence of expo-
sures that modify effects of other risk factors.
We propose that risk factors associated with colon cancer
at the population level exist in a shifting context. We
hypothesize that the ability of studies to estimate the
influence of risk factors for colon cancer depends on the
presence of effect-measure modifiers that are changing in
the population. We hypothesize that change in the esti-
mated relative risk from a given exposure can occur if
prevalence of other exposures that modify its risk are
changing. Thus, it is possible that differences in risk fac-
tors identified between studies can be attributed, at least
in part, to differences in the prevalence of important pop-
ulation characteristics.
Changes in U.S. population during the last quarter of the
20th century in diet, physical activity, and weight, charac-
teristics that affect colon cancer risk, have been described
based on national surveys [16]. In this paper we examine
changes in the use of aspirin, HRT, and obesity in popula-
tion-based samples from two western states between the
early 1990s and the late 1990s. Data from these popula-
tions were rigorously collected using the same question-
naire and recruitment methods. We evaluate trends in use
of HRT and aspirin over the last three decades of the 20th
century as reported in the literature and in National
Health and Nutrition Examination Survey (NHANES)
data.
To test our hypothesis that effect-measure modifiers can
influence population level risk of other factors, we con-
sider the inter-relationships of aspirin and other NSAID
use, BMI, and HRT in altering the risk of colon cancer. We
focus particularly on these factors since their prevalence
has changed dramatically over the past decades and they
appear to play a major role in modulating colon cancer
risk factors.
Methods
Study Population
Data from two case-control study populations are
included in these analyses[17,18]: a population-based
case-control study of colon cancer of cases and controls
selected between 1991 and 1994 and a population-based
case-control study of rectal cancer where cases and con-
trols were identified between 1997 and 2000. Both studies
used identical methods to identify, recruit, and interview
study participants. In both studies, participants were
asked to recall exposures two years prior to the date of
selection for the study. Methods for both studies have
been described in the published literature and are summa-
rized below[19,20]. The colon cancer study data were
used to estimate associations, including effect-measure
modification or interaction between exposures. Controls
from both cases-control studies were used to estimate
changes in exposures over time. Participants in both stud-
ies were from the Kaiser Permanente Medical Care Pro-
gram of Northern California (KPMCP) and the state of
Utah. Response rates for controls from the two studies
were comparable.
The colon cancer study included cases with a first primary
of colon cancer (International Classification of Diseases
of Oncology, 2nd edition codes 18.0, 18.2 to 18.9) diag-
nosed between October 1, 1991 and September 30, 1994.
The rectal cancer study included cases with a first primary
tumor in the rectosigmoid junction or rectum diagnosed
between May 1997 and May 2001. For both studies, con-
trols were frequency-matched on sex and 5-year age group
to the cases. Case eligibility was determined by the Sur-Epidemiologic Perspectives & Innovations 2007, 4:10 http://www.epi-perspectives.com/content/4/1/10
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veillance Epidemiology and End Results (SEER) Cancer
Registries in Northern California and in Utah and identi-
fied using a rapid-reporting system. At the KPMCP, con-
trols were randomly selected from membership lists. In
Utah controls 65 years and older were randomly selected
from Health Care Finance Administration (HCFA) lists
and controls younger than 65 were randomly selected
from driver's license lists. To be eligible for the study, par-
ticipants had to be between 30 and 79 years of age at time
of diagnosis, English speaking, mentally competent to
complete the interview, and could not have had previous
colorectal cancer. Cases with known (as indicated on the
pathology report) familial adenomatous polyposis, ulcer-
ative colitis, or Crohn's disease were excluded.
A total of 1346 colon cancer cases and 1544 matched con-
trols were interviewed between January 1991 and Decem-
ber 1994 and 952 cases and 1205 controls were
interviewed between October 1997 and January 2002 as
part of the rectal cancer study and are included in these
analyses. Of participants contacted between 1991 and
1994, 80.8% of cases and 71.8% of controls participated;
between 1997 and 2001, 68.8% of controls participated.
Data Collection
Data were collected by trained and certified interviewers
using laptop computers. For both the colon and rectal
cancer studies, data were collected in an identical manner,
using the same study questionnaire and the same quality
control procedures [19-21]. The interview took approxi-
mately two hours. Quality control methods were used in
both studies to assure that interview procedures were
implemented consistently and have been described in
detail [19,20].
For both studies, dietary intake was ascertained using an
adaptation of the CARDIA diet history [20,22,23]. Partic-
ipants were asked to recall foods eaten, the frequency
which they were eaten, serving size, and if fats were added
in the preparation. Nutrient information was obtained by
converting food intake data into nutrient data using the
Minnesota Nutrition Coding Center (NCC) nutrient data-
base. Height and weight were measured at the time of
interview and weight also was reported for the two and
five years prior to interview. The body mass index (BMI)
of kg/m2 was calculated for men and women. Other infor-
mation of relevance to this analysis included reproductive
history, use of aspirin and NSAIDs on a regular basis, and
physical activity [24]. The interview included questions
for women on the use of exogenous hormones such as
estrogen, progestin, or other female hormones for both
contraceptive and non-contraceptive purposes. Dates of
first and last use and duration of use of HRT were ascer-
tained. Menopause history including reason for meno-
pause, natural or surgery, and age at menopause, was
obtained.
Statistical Methods
To evaluate differences in population characteristics for
the two time periods (i.e. 1991–1994 and 1997–2001),
we compare exposure prevalence among controls after
adjusting for possible age and sex differences. Variables
assessed included variables thought to be important
effect-measure modifiers of other variables. These
included, BMI, physical activity, NSAID use (includes use
of aspirin), and HRT use among post-menopausal
women.
In order to describe population changes in exposures to
these factors over a longer time period, we used results
from national surveys conducted in the U.S., and the pub-
lished literature, to obtain estimates of exposure preva-
lence for obesity and NSAID use in the 1970s and 1980s.
BMI for men and women was available from the NHANES
surveys [25]. We could not find suitable national survey
data to estimate changes in the prevalence of aspirin use.
Although NHANES surveys have asked about aspirin use,
NHANES surveys over this time period have used ques-
tions with different definitions of aspirin use, and differ-
ent groupings of aspirin, acetominophen, and other
NSAIDs, so that the data are not comparable over time.
We therefore estimated prevalence of NSAID use in the
1970s and 1980s as reported from other population-
based studies that used questions similar to those in our
own studies [26,27].
For colon cancer relative risk associations, reported weight
for the period two years prior to diagnosis was used to cal-
culate BMI. Using aspirin or non-steroidal anti-inflamma-
tory drugs on a regular basis (defined as at least three
times per week for one month) within two years prior to
diagnosis was considered positive use, while those not
using aspirin or non-steroidal anti-inflammatory drugs
during this time period were considered non-users. HRT
use was defined as having used HRT within the past two
years. Data were categorized into groups based on
respondent response to using aspirin/NSAIDs, HRT, and
BMI cut-points of 25 and 30. For physical activity levels
and western diet, categories were based on distribution of
these continuous variables as reported for the colon can-
cer study.
To provide an example of the potential for risk estimates
to change due to change in the prevalence of effect-meas-
ure modifiers, we estimated odds ratios for the relative
risk of colon cancer associated with obesity (BMI ≥ 30)
compared to individuals whose BMI was ≤ 23 stratified by
HRT users and non-users and by NSAID/aspirin users and
nonusers. Unconditional logistic regression models wereEpidemiologic Perspectives & Innovations 2007, 4:10 http://www.epi-perspectives.com/content/4/1/10
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used to estimate odds ratios associated with effect-modifi-
cation adjusting for confounding factors that included
energy intake, physical activity level, dietary calcium and
fiber, HRT (NSAID/aspirin model), and NSAIDs/aspirin
(HRT use only model). Statistical testing for interaction
was determined by the relative excess risk from interaction
(RERI) [28,29]. The RERI was used to estimate the relative
strength of the interactive effect and can be interpreted as
the excess risk due to interaction relative to the risk with-
out exposure. Using this model risk estimates are esti-
mated for exposures with and without the presence of
other exposures and it is estimated if the difference
between the combined exposures are greater or less than
would be expected when the risk from the two independ-
ent exposures are added. Statistical analyses were done
using SAS statistical software (Cary, NC).
To illustrate the impact of changes in prevalence of use of
aspirin and HRT over time on risk estimates for other risk
factors, we estimated ORs for BMI (highest quartile vs.
lowest) in hypothetical populations with different preva-
lence of NSAID/aspirin and HRT use. To develop these
estimates we used the ORs for obesity or a BMI of 30 or
more relative to those with a BMI of 23 or less that were
observed in our study population. These risk estimates
were calculated within strata of NSAID/aspirin users (risk
estimate used was 2.5 from the stratified model) and non-
users (risk estimate of 1.2 used from stratified model) and
HRT users (risk estimate of 2.1 used for strata of users)
and non-users (risk estimate of 0.8 used for strata of non-
users). We assumed that risk estimates for BMI within
these circumstances would be constant, although varia-
tion in exposure to NSAID/aspirin and HRT use in the
population would influence the actual BMI detected risk.
We calculated the population risk as the variable expo-
sures of NSAIDS/aspirin and HRT using population distri-
butions of 5% users, 95% non-users, then a population
with 10% aspirin users, 90% non-users, etc. Additional
File 1 shows the calculation for these estimates. These pre-
dicted population ORs are shown over a range of percent-
ages of use of NSAIDs and HRT that are comparable to
changes reported in these exposures over time.
Results
Figure 1 illustrates changes in obesity and aspirin use over
the last two decades. Prevalence of obesity comes from
NHANES data and data from our two control popula-
tions. In a 30 year time period, the prevalence of obesity
has doubled. The prevalence of aspirin use dramatically
increased between population-based studies conducted in
the late 1970s and early 1980s, in which use was reported
at 7% [26] and 15% [27] respectively, and one conducted
in 1997–2000, in which use was over 40%. Our data dem-
onstrate the dramatic change in reported use of HRT,
increasing from 35.6% of post-menopausal women in
1991–1994 to 50.7% in 1997–2000 (Table 1). We further
evaluated the joint distribution of risk factors over time,
using data from the control subjects (Tables 2 and 3).
We detected a significant interaction between NSAID use
and HRT on colon cancer relative risk (RERI p value 0.06)
(Table 4). The interaction is such that the only observed
increased in colon cancer relative risk from (OR 2.0 95%
CI 1.3–2.9) is among women who use neither NSAIDs
nor HRT. Not using HRT did not result in an increased rel-
ative risk of colon cancer among women who used
NSAIDs on a regular basis.
Table 1: BMI (kg/m2), HRT use, and current NSAID/aspirin use 
reported during 1991–1994 and 1997–2001 by two population-
based control groups1
1991–1994 1997–2000 p value2
N (%)3 N (%)
NSAIDs/aspirin: No 938 (60.8) 692 (57.6) 0.02
Yes 605 (39.2) 510 (42.4)
HRT use: No 364 (64.4) 188 (49.3) <0.01
Yes 201 (35.6) 193 (50.7)
BMI1 ≤ 23 287 (18.8) 173 (14.5) <0.01
24–25 272 (17.8) 174 (14.6)
26–29 507 (33.2) 427 (35.9)
≥ 30 461 (30.2) 417 (35.0)
1Data from controls participating in population-based studies of colon 
and rectal cancer in Utah and Northern California [18]
2p values based on χ2 statistic from contingency tables with Mantel-
Haenszel adjustment.
3Numbers vary slightly because of missing data for the various 
variables; HRT use is limited to data from post-menopausal women.
Changes in obesity and aspirin use between 1970 and 2000 in  U. S. populations Figure 1
Changes in obesity and aspirin use between 1970 and 2000 in 
U. S. populations. Obesity data prior to 1991 from NHANES 
[25], for 1991–94 from colon cancer case-control study [17], 
and for 1999–2000 from rectal cancer study [42]. Aspirin 
data from 1970s and 1980 from references [26, 27] and for 
1991–94 from colon cancer case-control study [17], and for 
1999–2000 from rectal cancer study [42].
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Odds ratios for associations between BMI and colon can-
cer relative risk differed significantly between subjects
who did and did not use NSAIDS and HRT (Table 5).
Among those who used NSAIDs on a regular basis, obesity
significantly increased relative risk of colon cancer while
among non-users there was little increase in risk associ-
ated with being obese. Similarly for HRT users, there was
a significant increase relative risk associated with obesity
while among post-menopausal women who did not use
HRT, there was no increased relative risk associated with
obesity.
Figure 2 illustrates the relative risk associated with obesity
by various levels of exposure to NSAIDs and HRT. We esti-
mate that for a population in which 5% use aspirin or
NSAIDs, the overall OR for obesity (BMI of 30 or more)
that would be detected would be less than 1.3, while the
OR that would be detected at the population level would
increase to over 1.8 in a population with 50% NSAIDs
users. Similarly, the OR for obesity among women in a
population with few HRT users that would be detected
would be close to null, but would increase to 1.45 among
women if the prevalence of HRT use was 50%.
Conclusion
We have demonstrated using data from our studies and
the literature that BMI, HRT use, and aspirin use have
changed over time. In addition to documenting these
changes, we have shown, through assessment of interac-
tion, the potential impact of those changes on ORs for
colon cancer relative risk estimates in the population. The
presence of exposures such as aspirin and HRT use appear
to modify relative risk associated with other the important
colon cancer relative risk factors such as obesity. There-
fore, changes in prevalence of aspirin and HRT use over
time will affect colon cancer relative risk estimates associ-
ated with these other factors. The result of multiple risk
factors changing overtime further illustrate the complexity
of multi-factorial diseases, such as colon cancer, both in
terms of risk factor identification and in understanding
the disease process itself.
As documented here and by others, important diet and
lifestyle factors that are associated with colorectal cancer
have changed over time [16,30-33]. Obesity has been doc-
umented as increasing worldwide [34]. In the study by
Cronin and colleagues[16], changes in five colon cancer
Table 3: BMI among current NSAID/aspirin users and non-users in 1991–1994 and in 1997–2001 [17, 18]
1991–1994 1997–2001
NSAIDs/aspirin Yes 
(39% of population) N (%)
NSAIDs/aspirin No 
(61% of population) N (%)
NSAIDs/aspirin Yes 
(42% of population) N (%)
NSAIDs/aspirin No 
(58% of population) N (%)
P value1
BMI (kg/m2)
≤ 23 113 (19.0) 174 (18.7) 63 (12.5) 109 (16.0) 0.65
24–25 104 (17.5) 168 (18.1) 73 (14.5) 99 (14.5)
26–29 200 (33.6) 306 (32.9) 181 (35.8) 246 (36.0)
≥ 30 178 (29.9) 283 (30.4) 188 (37.2) 229 (33.5)
1p value compares differences in distribution over time using a χ2 statistic.
Table 2: BMI and current NSAID/aspirin use stratified by HRT users and non-users1 in 1991–1994 and 1997–2001 [17, 18]
1991–1994 1997–2001
HRT Yes 
(36% of population) N (%)
HRT No 
(648% of population) N (%)
HRT Yes 
(51% of population) N (%)
HRT No 
(49% of population) N (%)
P value2
BMI (kg/m2)
≤ 23 49 (25.0) 80 (22.4) 41 (21.9) 32 (17.2) <0.01
24–25 36 (18.4) 59 (16.5) 28 (15.0) 30 (16.1)
26–29 56 (28.6) 98 (27.5) 64 (34.2) 55 (29.6)
≥ 30 55 (28.1) 120 (33.6) 54 (28.9) 69 (37.1)
NSAIDs/aspirin
Yes 91 (45.3) 137 (37.7) 93 (48.2) 85 (45.7) <0.01
No 110 (54.7) 226 (62.3) 100 (51.8) 101 (54.3)
1Restricted to post-menopausal women
2p value compares differences in distribution over time using a χ2 statistic.Epidemiologic Perspectives & Innovations 2007, 4:10 http://www.epi-perspectives.com/content/4/1/10
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risk factors, vegetable intake, red meat intake, physical
activity, weight, and alcohol, were evaluated over a 20-
year time period. Although they noted that changes had
occurred in these factors over time, they summarized that
the overall effect on colon cancer incidence associated
with these changes was minimal since changes in risk and
protective factors offset each other. They did not evaluate
the impact of effect-measure modification when factors
such as NSAIDs that change over time modify the
observed relative risk associated with other exposures.
Looking at a similar time period as we did in this study, Li
and colleagues evaluated changes in diet, physical activity,
and weight between 1990 and 1996 [35]. They observed
that increases in fruit and vegetable intake were restricted
to those who were active and had a normal weight, sug-
gesting that differential shifts in the population are occur-
ring.
Few studies have reported on changes in aspirin or HRT
use over time and different definitions of regular use make
comparisons across studies difficult. One of the first stud-
ies to detect an association between aspirin use and colon
cancer was conducted by Rosenberg and colleagues who
reported 7% of the population using aspirin in the late
1970s [26]. In 1976 the National Health Survey observed
that roughly 20% of the population used any aspirin [36].
A survey conducted in Minnesota in 1981–82 indicated
that among those between 55 and 74 years 14.6% of
women and 13.6% of men took aspirin regularly (at least
7 of the prior 14 days), and that this increased to 19.8 %
Table 5: Colon cancer relative risk associated with BMI (kg/m2), by NSAID/aspirin and HRT use,1991–1994
NSAIDS/Aspirin Everyone Adjusted Yes No Yes No
Case/Control N OR (95% CI)1 Case/Control N Case/Control N OR (95% CI)
BMI ≤ 23 202/307 1.0 41/115 161/192 1.0 2.4 (1.6,3.6)
24–25 233/296 1.2 (0.9–1.5) 71/120 162/176 1.6 (1.02,2.6) 2.5 (1.6,3.8)
26–29 459/528 1.3 (1.0–1.6) 136/189 323/339 1.9 (1.3,3.0) 2.6 (1.7,3.8)
≥ 30 443/404 1.6 (1.2–2.0) 179/177 264/227 2.7 (1.8,4.1) 3.0 (2.0,4.5)
RERI2(95% CI); p value -1.09 (-2.30, 0.11); 0.07
HRT3 Everyone Adjusted Yes No Yes No
Case/Control N OR (95% CI)4 Case/Control N Case/Control N OR (95% CI) OR (95% CI)
BMI ≤ 23 109/145 1.0 27/64 82/81 1.0 2.6 (1.5,4.6)
24–25 97/109 1.2 (0.8–1.7) 39/44 58/66 2.1 (1.1,4.0) 2.3 (1.3,4.1)
26–29 139/151 1.2 (0.9–1.7) 35/49 105/102 1.7 (0.9,3.3) 2.6 (1.5,4.5)
≥ 30 137/154 1.1 (0.8–1.5) 37/41 100/113 2.1 (1.1,4.0) 2.1 (1.2,3.5)
RERI4 (95% CI); p value -1.68 (-3.53,0.17); 0.07
1Adjusted for age, sex, energy intake, physical activity level, dietary calcium and fiber, NSAIDs/aspirin
2Relative excess risk from interaction, a measure of the amount of effect-measure modification on the additive scale. A value of zero would 
represent no difference in ORs.
3Analysis restricted to post-menopausal women
4Adjusted for age, sex, energy intake, physical activity level, dietary calcium and fiber, NSAIDs/aspirin, and HRT; restricted to post-menopausal 
women
Table 4: Relative risk of colon cancer associated with NSAID/aspirin and HRT use, and their interaction, among post-menopausal 
women only, 1991–1994
All post-menopausal women NSAID/aspirin Use Stratified
Cases/Controls (N) Adjusted Case/Control (N) Yes No
OR (95% CI) Yes No OR1 (95% CI) OR1 (95% CI)
HRT use Yes 138/198 1.0 52/89 86/109 1.0 1.3 (0.8–2.0)
No 344/361 1.4 (1.0–1.8) 90/136 254/225 1.1 (0.7–1.7) 2.0 (1.3–2.9)
RERI2 (95% CI);p value f (-0.03, 1.21);0.06
1Adjusted for age, energy intake, physical activity level, BMI, dietary calcium and fiber and NSAIDs/aspirin.
2Relative excess risk for interaction, a measure of the amount of effect-measure modification on the additive scale. A value of zero would represent 
no difference in ORs.Epidemiologic Perspectives & Innovations 2007, 4:10 http://www.epi-perspectives.com/content/4/1/10
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and 19.4% by 1985–86 [37]. That study noted that an
increase in the proportion of study participants who
reported use of aspirin for cardiovascular disease protec-
tion accounted for much of the change. A study of nurses
reported that 11.6% of those younger than 52 years
reported using NSAIDs over 3 times a week in 1997 and
18.8% and 27.9% of nurses over 52 years reported NSAID
and aspirin use over 3 times per week [29,38]. In the late
1990s, NSAID use 3 or more times per week for at least
one month was reported by 42% of our study population.
Although difficulties in monitoring trends in aspirin use
exist, taken together these reports are consistent with an
upward trend in use over this time period.
While our study data indicate that HRT use increased dur-
ing the 1990s, recent research findings regarding potential
adverse effects from HRT use [39] are resulting in a dra-
matic reduction in the proportion of post-menopausal
women using HRT[40]. Estrogen and HRT also have been
identified as important modifiers of other risk factors,
such as obesity, and may explain many of the differences
in colon cancer obesity associations observed for men and
women [10,11].
There are several strengths to the study, including a large
sample to look at interactions to test our hypothesis, and
the ability to look at data collected in the same manner
from two population-based control groups, to identify
exposure changes overtime. Response rates were slightly
lower for the rectal cancer study than for the colon cancer
study, although good response rates overall were obtained
in both studies. However, because the study in the early
1990s was one of colon cancer and the one in the late
1990s was of rectal, we are unable to directly calculate rel-
ative risk estimates for the two time periods at the popu-
lation level.
These findings also have important study design and anal-
ysis implications because they suggest that disease associ-
ations are complicated when factors that modify risk
change. Aspirin, NSAID, and HRT use are examples of
these types of effect-measure modifiers. Our results sug-
gest that the risks associated with obesity and HRT is influ-
enced by NSAIDs. In this scenario, case-control studies
provide a snapshot of what risk factors are in the popula-
tion at a given point in time. Studies with sufficiently large
sample size can define subsets of the population that have
different characteristics. Cohort studies accumulate cases
over time; in order to take into account changing popula-
tion characteristics, changes in risk factors for should be
taken into account by incorporating repeated exposure
measurements. The importance of identification of effect-
measure modification should be stressed since results can
have implications for understanding the data and the dis-
ease process. Often evaluation of effect-measure modifica-
tion is secondary and stratified estimates are not
presented unless significant effect-measure modification
is detected. However, studies are often underpowered to
detect statistically significant effect-measure modification
[41]. When effect-measure modification between two risk
factors has been reported, stratified odds ratios should be
reported so that results can be compared between studies.
Failure to evaluate effect-measure modification when
knowledge of biological mechanisms, or prior data, sug-
gest that it exists may lead to inability to recognize and
understand associations that are important.
In summary, populations are dynamic and risk factors
exist in a shifting context. Of particular importance are
factors that modify the risk of other factors. NSAID use,
HRT, and obesity are three factors that appear to be chang-
ing over time as well as having an impact as effect-meas-
ure modifiers of other diet and lifestyle factors. The
impact of population changes on the epidemiologic liter-
ature can be kept to a minimum if investigators assess
exposure-disease associations within strata of other expo-
sures, and present results in a manner that allows compar-
isons across studies.
Predicted ORs for colon cancer associated with obesity (BMI  ≥ 30 kg/m2 versus lowest quartile, BMI ≤ 23 kg/m2) where  obesity is held constant but with varying prevalence of  NSAID or HRT use Figure 2
Predicted ORs for colon cancer associated with obesity (BMI 
≥ 30 kg/m2 versus lowest quartile, BMI ≤ 23 kg/m2) where 
obesity is held constant but with varying prevalence of 
NSAID or HRT use. ORs calculated from multiple logistic 
regression models for stratum-specific ORs for obesity in 
users and non-users of aspirin, and users and non-users of 
HRT among post-menopausal women. Adjusted for age, sex 
(NSAIDS/aspirin use only), energy intake, physical activity 
level, dietary calcium and fiber, NSAIDs/aspirin (HRT model 
only).
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